OmniAb, Inc. (OABI)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$4.66-2.51%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge OmniAb, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	3.85M
EPS	—	-0.131
FY 2026 · Annual
Revenue	$32M–$36M	35.16M
EPS	—	-0.361
Operating expenses	$51M–$55Mnon-GAAP	—
FY 2027 · Annual
Revenue	—	43.91M
EPS	—	-0.268

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Cash and equivalents at least $33 million by end 2026	Cash targets also improved to $33-38 million by year-end 2026.	Intact	Cash falls below $33 million at end of 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Cash and equivalents guidance increased from $30-$35 million in 2026-Q1 to $37-$41 million in 2026-Q2. Actual cash and short-term investments were $52 million at 2026-Q2. Management is delivering improved cash position guidance consistent with stated priorities. Delivery assessment Oct 24, 2026
EPS loss narrows toward -$0.32 or better by 2027	A supporting condition in OmniAb, Inc.'s published investment case. The stated target is <= -0.32 USD_PER_SHARE.	Improving	EPS loss worsens beyond -$0.32 in FY27	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue reaches at least $28 million in 2026	A primary condition in OmniAb, Inc.'s published investment case. The stated target is >=28 USD_MILLIONS.	Intact	Revenue falls below $28 million in FY26	Revenue: $13.415M FY2026-Q2; GAAP. Published target: >=28 USD_MILLIONS. Target period is not explicitly aligned with this observation. Source published Aug 6, 202613,415,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: bd39f801-3bdc-401e-8b48-013e163c4559. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Revenue increased from $8.1 million in first half 2025 to $27.8 million in first half 2026, driven by milestone revenue and new programs. Management raised 2026 revenue guidance twice, most recently to $32-$36 million, reflecting delivering trajectory. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue$0.04B

$0.05B → $0.04B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$46,106,500	4 / 6
2026-07-25	Unavailable	$46,106,500	4 / 6
2026-07-26	Unavailable	$46,106,500	4 / 6
2026-07-27	Unavailable	$46,106,500	4 / 6
2026-07-28	Unavailable	$46,106,500	4 / 5
2026-07-29	Unavailable	$46,106,500	4 / 6
2026-07-30	Unavailable	$46,106,500	4 / 6
2026-07-31	Unavailable	$46,106,500	4 / 5
2026-08-01	Unavailable	$46,106,500	4 / 5
2026-08-02	Unavailable	$46,106,500	4 / 6
2026-08-03	Unavailable	$46,106,500	4 / 5
2026-08-04	Unavailable	$46,106,500	4 / 6
2026-08-05	Unavailable	$46,106,500	4 / 5
2026-08-06	Unavailable	$46,106,500	4 / 5
2026-08-07	Unavailable	$46,106,500	4 / 5
2026-08-08	Unavailable	$46,106,500	4 / 6
2026-08-09	Unavailable	$46,106,500	4 / 6
2026-08-10	Unavailable	$46,106,500	4 / 5
2026-08-12	Unavailable	$46,106,500	4 / 5
2026-08-13	Unavailable	$43,295,500	4 / 6
2026-08-14	Unavailable	$46,106,500	4 / 5
2026-08-15	Unavailable	$46,106,500	4 / 5
2026-08-16	Unavailable	$46,106,500	4 / 5
2026-08-17	Unavailable	$46,106,500	4 / 5
2026-08-18	Unavailable	$46,106,500	4 / 5
2026-08-19	Unavailable	$46,106,500	4 / 5
2026-08-20	Unavailable	$43,491,500	3 / 5
2026-08-21	Unavailable	$43,491,500	3 / 5
2026-08-22	Unavailable	$43,491,500	3 / 5
2026-08-23	Unavailable	$43,491,500	3 / 5
2026-08-24	Unavailable	$43,491,500	3 / 5
2026-08-25	Unavailable	$43,491,500	3 / 5
2026-08-26	Unavailable	$43,491,500	3 / 5
2026-08-27	Unavailable	$43,491,500	3 / 5
2026-08-28	Unavailable	$43,491,500	3 / 5
2026-08-29	Unavailable	$43,491,500	3 / 5
2026-08-30	Unavailable	$43,491,500	3 / 5
2026-08-31	Unavailable	$43,491,500	3 / 5
2026-09-01	Unavailable	$43,491,500	3 / 5
2026-09-02	Unavailable	$43,491,500	3 / 5
2026-09-03	Unavailable	$43,491,500	3 / 5
2026-09-04	Unavailable	$43,491,500	3 / 5
2026-09-05	Unavailable	$43,491,500	3 / 5
2026-09-06	Unavailable	$43,491,500	3 / 5
2026-09-07	Unavailable	$43,491,500	3 / 5
2026-09-08	Unavailable	$43,491,500	3 / 5
2026-09-09	Unavailable	$43,491,500	3 / 5
2026-09-10	Unavailable	$43,491,500	3 / 5
2026-09-11	Unavailable	$43,491,500	3 / 5
2026-09-12	Unavailable	$43,491,500	3 / 5
2026-09-13	Unavailable	$43,491,500	3 / 5
2026-09-14	Unavailable	$43,491,500	3 / 5
2026-09-15	Unavailable	$43,491,500	3 / 5
2026-09-16	Unavailable	$43,491,500	3 / 5
2026-09-17	Unavailable	$43,491,500	3 / 5
2026-09-18	Unavailable	$43,491,500	3 / 5
2026-09-19	Unavailable	$43,491,500	3 / 5
2026-09-20	Unavailable	$43,491,500	3 / 5
2026-09-21	Unavailable	$43,491,500	3 / 5
2026-09-22	Unavailable	$43,491,500	3 / 5
2026-09-23	Unavailable	$43,491,500	3 / 5
2026-09-24	Unavailable	$43,491,500	3 / 5
2026-09-25	Unavailable	$43,491,500	3 / 5
2026-09-26	Unavailable	$43,491,500	3 / 5
2026-09-27	Unavailable	$43,491,500	3 / 5
2026-09-28	Unavailable	$43,491,500	3 / 5
2026-09-29	Unavailable	$43,491,500	3 / 5
2026-09-30	Unavailable	$43,491,500	3 / 5
2026-10-01	Unavailable	$43,491,500	3 / 5
2026-10-02	Unavailable	$43,491,500	3 / 5
2026-10-03	Unavailable	$43,491,500	3 / 5
2026-10-04	Unavailable	$43,491,500	3 / 5
2026-10-05	Unavailable	$43,491,500	3 / 5
2026-10-06	Unavailable	$43,491,500	3 / 5
2026-10-07	Unavailable	$43,491,500	3 / 5
2026-10-08	Unavailable	$43,491,500	3 / 5
2026-10-09	Unavailable	$43,912,333	3 / 5
2026-10-10	Unavailable	$43,912,333	3 / 5
2026-10-11	Unavailable	$43,912,333	3 / 5
2026-10-12	Unavailable	$43,912,333	3 / 5
2026-10-13	Unavailable	$43,912,333	3 / 5
2026-10-14	Unavailable	$43,912,333	3 / 5
2026-10-15	Unavailable	$43,912,333	3 / 5
2026-10-16	Unavailable	$43,912,333	3 / 5
2026-10-17	Unavailable	$43,912,333	3 / 5
2026-10-18	Unavailable	$43,912,333	3 / 5
2026-10-19	Unavailable	$43,912,333	3 / 5
2026-10-20	Unavailable	$43,912,333	3 / 5
2026-10-21	Unavailable	$43,912,333	3 / 5
2026-10-22	Unavailable	$43,912,333	3 / 5
2026-10-23	Unavailable	$43,912,333	3 / 5
2026-10-24	Unavailable	$43,912,333	3 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	7	0	0
2026-06-01	7	0	0
2026-07-01	7	0	0
2026-08-01	7	0	0
2026-09-01	7	0	0
2026-10-01	7	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades2 maintains

Recent actions · Sep 25–Oct 24 · 2 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Cash and equivalents at least $33 million by end 2026Direct metric needs a verified mapping
EPS loss narrows toward -$0.32 or better by 2027Direct metric needs a verified mapping
Revenue reaches at least $28 million in 2026Revenue: $13.415M

Next proof point

Oct 30, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.4%Typical daily move · historical

Downside history

-37.0%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

OmniAb, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk, early-stage growth business, not an established earnings compounder, because it is still loss-making. The thesis is intact, with management delivering revenue and cash guidance increases, but evidence is limited and confidence is medium.

What's priced into OmniAb, Inc.

The valuation is stretched, at a 1.71-times premium versus peers, and the expectations gap is modest at 0.12. That suggests the market already gives credit for improving execution and a supportive Healthcare backdrop, leaving less room for disappointment.

What the fundamentals likely do

Near-term, revenue growth and stronger cash guidance support the business: first-half revenue rose from $8.1 million to $27.8 million, and cash and short-term investments were $52 million at the end of the second quarter. Costs show mixed progress, and the company remains loss-making; the next results carry meaningful miss risk in a high-miss-rate industry.

What OmniAb, Inc. hinges on

Over the next few quarters, the thesis depends on OABI sustaining the delivery that led management to raise 2026 revenue guidance twice, without reversing that guidance. A weakening jobs report could add pressure to cyclical Healthcare names, while continued strong results and guidance from sector bellwethers could support the sector backdrop.